Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Ahrén, Bo LU (2007) In Current Diabetes Reports 7(5). p.340-347
Abstract
Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Current Diabetes Reports
volume
7
issue
5
pages
340 - 347
publisher
Current Science, Inc.
external identifiers
  • pmid:18173966
  • scopus:36749042536
ISSN
1539-0829
language
English
LU publication?
yes
id
a318cac6-ff4f-4d44-92ed-a80f7400056c (old id 1021637)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18173966?dopt=Abstract
date added to LUP
2016-04-04 08:39:23
date last changed
2024-01-12 05:42:55
@article{a318cac6-ff4f-4d44-92ed-a80f7400056c,
  abstract     = {{Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.}},
  author       = {{Ahrén, Bo}},
  issn         = {{1539-0829}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{340--347}},
  publisher    = {{Current Science, Inc.}},
  series       = {{Current Diabetes Reports}},
  title        = {{GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.}},
  url          = {{http://www.ncbi.nlm.nih.gov/pubmed/18173966?dopt=Abstract}},
  volume       = {{7}},
  year         = {{2007}},
}